ArticleJournal of veterinary internal medicine2026
Melioidosis in dogs and cats: 18 cases.
Article in Journal of veterinary internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe clinical manifestations and outcomes in dogs and cats with melioidosis have not been described. HYPOTHESIS/
objectivesDescribe the presenting signs, treatment, and outcome of dogs and cats with melioidosis. ANIMALS: Fifteen dogs and 3 cats from a hospital in Singapore.
methodsRetrospective case series. A hospital database search was performed to identify dogs with melioidosis presenting over a 5-year period. Data collected included signalment, clinical signs, test results, treatment, and outcome.
resultsDiagnosis was based on positive bacterial culture and identification of Burkholderia pseudomallei in all cases. At presentation, 13/15 (87%) had systemic inflammatory response syndrome (SIRS), 10/15 (67%) were septic, and 3/15 (20%) had septic shock. In dogs, 8/15 (53%) had multiple cutaneous abscesses or open wounds, and 6/15 (40%) had prostatitis or prostatic abscessation. In cats, 2/3 had osteomyelitis and 1/3 had pyelonephritis. Of the cases, 5/15 (33%) dogs and none of the cats were considered potentially immunocompromised. Of the 17 cases with >4 weeks of follow-up, death or euthanasia attributed to melioidosis occurred in 8/17 (47%). Of the surviving 9/17 (53%) animals, 6 were alive after 1 month (range, 1-43 months) and 3 died or were euthanized for reasons unrelated to melioidosis, with median follow-up duration of 724 days. CONCLUSIONS AND CLINICAL IMPORTANCE: Melioidosis should be considered in dogs with prostatitis or cutaneous abscesses, and in cats with osteomyelitis. Initial treatment with ceftazidime or meropenem, followed by 3-6 months of trimethoprim-sulfonamide (TMPS) might be optimal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.